Bioxytran Reports Significant Financial Losses and Increased Liabilities in Latest 10-Q Filing

Bioxytran, Inc. has reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $619,929 for the three months ended June 30, 2026, compared to a net profit of $35,439 for the same period in 2025. For the six months ending June 30, 2026, the net loss increased to $2,688,918, up from a loss of $1,318,196 in the prior year. The company's accumulated deficit has also grown to $23,733,164, compared to $21,044,246 at the end of 2025. This deterioration in financial performance is attributed to increased operating expenses, particularly a one-time stock-based compensation expense of $1,278,600 awarded to the CEO as a performance grant.

In terms of operational metrics, Bioxytran's total current assets decreased to $177,384 as of June 30, 2026, down from $509,914 at the end of 2025. The company's total liabilities surged to $5,274,697, compared to $3,249,894 at the end of the previous fiscal year. This increase in liabilities includes a significant rise in accounts payable and accrued expenses, which reached $1,198,685, up from $824,278. The company has not generated any revenue from operations since its inception, which raises substantial doubt about its ability to continue as a going concern.

Strategically, Bioxytran has been focused on developing its product pipeline, particularly in the area of therapeutic molecules for stroke treatment. The company is advancing its lead candidate, BXT-25, which is designed to be an injectable anti-necrosis drug. The company has also made progress in clinical trials, with an IND approved by the FDA for a trial expected to start in the third quarter of 2026. However, the company acknowledges that it needs to raise approximately $3.7 million to sustain its operations and continue its development activities over the next 15 months.

The company has taken steps to raise capital, including private placements that generated $314,533 in the first half of 2026. This included $191,047 from stock sales and $123,486 from warrants. However, the company is aware that its current cash reserves will not be sufficient to fund operations through September 2026. Bioxytran's management is actively pursuing additional funding options but has noted that there can be no assurance that these funds will be available on acceptable terms.

Looking ahead, Bioxytran's future hinges on its ability to secure additional financing to support its ongoing research and development efforts. The company has outlined several milestones, including the completion of clinical trials and potential commercialization of its products, but these plans are contingent on obtaining the necessary capital. The company’s financial statements reflect a critical need for funding, and without it, Bioxytran may be forced to scale back its operations or cease them altogether.